hydroxychloroquine has been researched along with Complications, Pregnancy in 111 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy." | 9.12 | Hydroxychloroquine in lupus pregnancy. ( Clowse, ME; Magder, L; Petri, M; Witter, F, 2006) |
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 9.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| "We conducted a randomized, controlled study to assess the need for hydroxychloroquine (HCQ) during lupus pregnancy and to assess safety." | 9.09 | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. ( Albuquerque, EM; Cataldo, MJ; Duarte, JL; Jesús, NR; Levy, RA; Ramos, RC; Tura, BR; Vilela, VS, 2001) |
| "The objective of this meta-analysis was to determine whether gestational use of hydroxychloroquine (HCQ) for autoimmune disorders leads to an increase in the risk for adverse pregnancy outcomes." | 8.93 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. ( Kaplan, YC; Koren, G; Nickel, C; Ozsarfati, J, 2016) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 8.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| " We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment." | 8.91 | Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? ( Botta, A; De Carolis, MP; De Carolis, S; Del Sordo, G; di Pasquo, E; Garufi, C; Lanzone, A; Salvi, S, 2015) |
| "The study objective was to evaluate the risk of major congenital malformations associated with exposure to hydroxychloroquine during the first trimester of pregnancy, the period of organogenesis." | 8.02 | Hydroxychloroquine early in pregnancy and risk of birth defects. ( Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Straub, L; Zhu, Y, 2021) |
| "Hydroxychloroquine was associated with a higher rate of live births and a lower prevalence of pregnancy complications in refractory primary obstetric APS." | 8.02 | The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. ( Alvarez, R; Balparda, J; Beruti, E; Fernandez Suarez, C; Gerde, M; Heer, C; Ibarra, E; Iglesias, M; Mac Kenzie, R; Rubinstein, F, 2021) |
| " Secondly, we estimated the prevalence of AVB among mothers with anti-Ro/La antibodies and examined the relationship of those fetal AVB with mother's use of hydroxychloroquine during pregnancy." | 7.91 | Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. ( Catoggio, LJ; Mollerach, FB; Rosa, J; Scolnik, M; Soriano, ER, 2019) |
| "Despite the heterogeneity in the 2 groups in terms of systemic lupus erythematosus prevalence and previous pregnancy history, our results support the concept that women with antiphospholipid antibodies may benefit from treatment with hydroxychloroquine during pregnancy to improve pregnancy outcome." | 7.83 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 7.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "To determine the effect of hydroxychloroquine treatment during pregnancy and lactation on babies of mothers affected by rheumatic diseases." | 7.73 | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. ( Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005) |
| "To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ)." | 7.69 | Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. ( Buchanan, NM; Hughes, GR; Kerslake, S; Khamashta, MA; Lima, F; Toubi, E, 1996) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 7.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 6.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| " Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy." | 6.47 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. ( Abarientos, C; Aronow, WS; Ash, JY; Chao, CP; Shapiro, DL; Sperber, K, 2011) |
| "Hydroxychloroquine (HCQ) is a valuable and possibly underused agent in treating mild lupus." | 5.29 | The use of hydroxychloroquine in lupus pregnancy: the British experience. ( Buchanan, NM; Hughes, GR; Khamashta, MA, 1996) |
| "Multiple guidelines recommend continuing hydroxychloroquine (HCQ) for SLE during pregnancy based on observational data." | 5.22 | Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. ( Balevic, S; Bay, C; Clowse, MEB; Eudy, AM; Fischer-Betz, R; Gladman, DD; Kosinski, A; Mokbel, A; Molad, Y; Nalli, C; Petri, M; Sanders-Schmidler, G; Tincani, A; Urowitz, M; van Noord, M, 2022) |
| "Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy." | 5.12 | Hydroxychloroquine in lupus pregnancy. ( Clowse, ME; Magder, L; Petri, M; Witter, F, 2006) |
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 5.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| "The use of hydroxychloroquine (HCQ) in pregnancy remains controversial." | 5.10 | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. ( Amoura, Z; Costedoat-Chalumeau, N; Denjoy, I; Duhaut, P; Huong, DL; Lupoglazoff, JM; Piette, JC; Sebbough, D; Vauthier, D; Wechsler, B, 2003) |
| "We conducted a randomized, controlled study to assess the need for hydroxychloroquine (HCQ) during lupus pregnancy and to assess safety." | 5.09 | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. ( Albuquerque, EM; Cataldo, MJ; Duarte, JL; Jesús, NR; Levy, RA; Ramos, RC; Tura, BR; Vilela, VS, 2001) |
| "It is safer to continue hydroxychloroquine rather than to discontinue this drug simply because of pregnancy." | 5.08 | Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. ( Parke, A; West, B, 1996) |
| "Current research in the field of systemic lupus erythematosus (SLE) and pregnancy focuses on predictors of adverse pregnancy outcomes, the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy and the importance of preconception counselling." | 5.05 | [Pregnancy with lupus erythematosus-an update]. ( Fischer-Betz, R; Haase, I, 2020) |
| "This review summarizes recent research in the field of systemic lupus erythematosus (SLE) and pregnancy with focus on clinical and biochemical predictors of adverse pregnancy outcomes (APOs), accumulating evidence for the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy, and the importance of preconception counseling." | 5.01 | Update on pregnancy complications in systemic lupus erythematosus. ( Marder, W, 2019) |
| " Hydroxychloroquine (HCQ) appears protective against flares in pregnancy, neonatal congenital heart block and preterm birth." | 5.01 | Systemic lupus erythematosus in pregnancy: high risk, high reward. ( Do, SC; Druzin, ML, 2019) |
| "The objective of this meta-analysis was to determine whether gestational use of hydroxychloroquine (HCQ) for autoimmune disorders leads to an increase in the risk for adverse pregnancy outcomes." | 4.93 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. ( Kaplan, YC; Koren, G; Nickel, C; Ozsarfati, J, 2016) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 4.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| "A great body of evidence suggest that hydroxychloroquine, sulfasalazine, and non-fluorinated steroids can be continued throughout pregnancy, while methotrexate and leflunomide should be discontinued 3 months before pregnancy." | 4.93 | Challenges and treatment options for rheumatoid arthritis during pregnancy. ( Gerosa, M; Meroni, PL; Schioppo, T, 2016) |
| " We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment." | 4.91 | Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? ( Botta, A; De Carolis, MP; De Carolis, S; Del Sordo, G; di Pasquo, E; Garufi, C; Lanzone, A; Salvi, S, 2015) |
| " A prospective study found great success in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients with quiet lupus nephritis." | 4.90 | Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. ( Clowse, ME; Peart, E, 2014) |
| " Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events." | 4.90 | Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? ( de Jesús, GR; de Jesús, NR; Levy, RA; Rodrigues, G, 2014) |
| "The use of Hydroxychloroquine (HCQ) during pregnancy has remained controversial for a long time." | 4.82 | [Pleading to maintain hydroxychloroquine throughout Lupus pregnancies]. ( Amoura, Z; Costedoat-Chalumeau, N; Le Thi Huong, D; Piette, JC; Wechsler, B, 2005) |
| "The study objective was to evaluate the risk of major congenital malformations associated with exposure to hydroxychloroquine during the first trimester of pregnancy, the period of organogenesis." | 4.02 | Hydroxychloroquine early in pregnancy and risk of birth defects. ( Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Straub, L; Zhu, Y, 2021) |
| "Hydroxychloroquine was associated with a higher rate of live births and a lower prevalence of pregnancy complications in refractory primary obstetric APS." | 4.02 | The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. ( Alvarez, R; Balparda, J; Beruti, E; Fernandez Suarez, C; Gerde, M; Heer, C; Ibarra, E; Iglesias, M; Mac Kenzie, R; Rubinstein, F, 2021) |
| " Hydroxychloroquine enhanced better neonatal outcomes and reduced adverse pregnancy outcomes and antenatal complications such as hypertension and diabetes." | 3.96 | New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre. ( Abd Rahman, R; Kamisan Atan, I; Min Tun, K; Mohamed Said, MS; Mustafar, R; Zainuddin, AA, 2020) |
| " Secondly, we estimated the prevalence of AVB among mothers with anti-Ro/La antibodies and examined the relationship of those fetal AVB with mother's use of hydroxychloroquine during pregnancy." | 3.91 | Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. ( Catoggio, LJ; Mollerach, FB; Rosa, J; Scolnik, M; Soriano, ER, 2019) |
| " Hydroxychloroquine (HCQ) reduces disease activity and flares; however, pregnancy causes significant physiologic changes that may alter HCQ levels and lead to therapeutic failure." | 3.91 | Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019) |
| "Despite the heterogeneity in the 2 groups in terms of systemic lupus erythematosus prevalence and previous pregnancy history, our results support the concept that women with antiphospholipid antibodies may benefit from treatment with hydroxychloroquine during pregnancy to improve pregnancy outcome." | 3.83 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016) |
| "Steroids and hydroxychloroquine remain the most widely prescribed treatment options in pregnancy, but the use of biologic agents is becoming increasingly common." | 3.83 | Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. ( Bateman, BT; Desai, RJ; Gopalakrishnan, C; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Patorno, E, 2016) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 3.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| " A 33-year-old G1 P0 with Cogan's syndrome experienced an uneventful pregnancy while being treated with hydroxychloroquine and prednisone." | 3.75 | Cogan's syndrome complicating pregnancy. ( Blackstone, J; Cartin, A; Currie, C; Pinette, MG; Wax, JR, 2009) |
| " hydroxychloroquine and/or prednisone) were continued during pregnancy." | 3.73 | [Perinatal consequences of maternal connective tissue diseases: a prospective study of 73 cases]. ( Costedoat-Chalumeau, N; de Montgolfier, I; Gold, F; Lapillonne, A; Renaud, C; Vautier-Brouzes, D, 2006) |
| "To determine the effect of hydroxychloroquine treatment during pregnancy and lactation on babies of mothers affected by rheumatic diseases." | 3.73 | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. ( Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005) |
| "To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ)." | 3.69 | Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. ( Buchanan, NM; Hughes, GR; Kerslake, S; Khamashta, MA; Lima, F; Toubi, E, 1996) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 3.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "Pregnancy was formerly discouraged in patients with SLE because of unstable disease activity during the gestation period, increased thrombosis risk, severe organ damage, and inevitable side effects of immunosuppressive agents." | 2.82 | Pregnancy-related complications in systemic lupus erythematosus. ( Cui, L; Li, Z; Liu, Q; Mu, R; Qiao, J; Tan, Y; Yang, S, 2022) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 2.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| "Management of thrombosis is based on long-term oral anticoagulation and patients with arterial events should be treated aggressively." | 2.53 | Current status and future prospects for the treatment of antiphospholipid syndrome. ( Al Marzooqi, A; Al Saleh, J; Khamashta, M; Leone, A, 2016) |
| "Adequate pregnancy care of women with systemic lupus erythematosus (SLE) rests on three pillars: a coordinated medical-obstetrical care, an agreed and well-defined management protocol and a good neonatal unit." | 2.47 | Lupus and pregnancy: integrating clues from the bench and bedside. ( Khamashta, MA; Ruiz-Irastorza, G, 2011) |
| " Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy." | 2.47 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. ( Abarientos, C; Aronow, WS; Ash, JY; Chao, CP; Shapiro, DL; Sperber, K, 2011) |
| "In the 1980's, pregnancies in systemic sclerosis (SSc) patients were considered to be at high risk for poor foetal and maternal outcome." | 2.44 | [Pregnancy in systemic sclerosis]. ( Bérezné, A; Mouthon, L, 2008) |
| "Common complications of systemic lupus erythematosus include nephritis, hematologic complications such as thrombocytopenia, and a variety of neurologic abnormalities." | 1.91 | Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. ( Craigo, S; Kuller, JA; Norton, ME; Osmundson, SS; Porter, F; Silver, R, 2023) |
| "To investigate the risk of gestational diabetes mellitus (GDM) associated with systemic lupus erythematosus (SLE) by comparing pregnancies in women with SLE to general population controls." | 1.72 | Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus. ( Arkema, EV; Gernaat, SAM; Simard, JF; Svenungsson, E; Wikström, AK, 2022) |
| "HCQ is safe for IgAN treatment during pregnancy with effective reduction of proteinuria." | 1.72 | The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Si, FL; Tang, C; Yao, YX; Zhang, H, 2022) |
| "Lupus nephritis was present in 20." | 1.62 | Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal. ( Barros, T; Braga, A; Braga, J; Carvalheira, G; Faria, R; Farinha, F; Marinho, A; Neves, E; Rocha, G; Vasconcelos, C, 2021) |
| "Few cases of systemic lupus erythematosus (SLE) pregnancy complicated by PA have been reported, and the background pathophysiology remains elusive." | 1.56 | Placenta accrete after a frozen-thawed embryo transfer in a systemic lupus erythematosus patient treated with hydroxychloroquine. ( Hiramitsu, S; Ishikawa, T; Iwahara, Y; Mano, C; Miyasaka, N; Saito, K; Sekiguchi, M; Tatsumi, T, 2020) |
| "Hydroxychloroquine use was associated with lower APOs including pre-eclampsia, prematurity and IUGR in the univariate analyses but it was no longer significant in the GEE analysis." | 1.56 | Adverse pregnancy outcomes among multi-ethnic systemic lupus erythematosus patients in Malaysia. ( Maulana, SA; Mohd, R; Mustafar, R; Rahman, RA; Said, MSM; Shaharir, SS; Shahril, NS, 2020) |
| "Antiphospholipid antibody syndrome is the most common type of acquired thrombophilia disease." | 1.48 | [Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome]. ( Li, XY; Liu, XY; Zhao, JX, 2018) |
| "The effect of additional treatments combined with conventional therapy on pregnancy outcomes was examined in high-risk primary antiphospholipid syndrome (PAPS) patients to identify the most effective treatment strategy." | 1.48 | Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. ( Alijotas-Reig, J; Andreoli, L; Bertero, MT; Costedoat-Chalumeau, N; Cuadrado, MJ; De Carolis, S; Gerosa, M; Grandone, E; Haladyj, E; Hoxha, A; Khamashta, MA; Latino, JO; Maina, A; Marozio, L; Mayer-Pickel, K; Mekinian, A; Meroni, PL; Morel, N; Pengo, V; Ramoni, V; Reshetnyak, T; Ruffatti, A; Sciascia, S; Serrano, F; Simchen, MJ; Tenti, S; Tincani, A; Tonello, M; Udry, S, 2018) |
| "Preterm birth was defined as a birth <37 weeks gestation." | 1.48 | Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. ( Clowse, MEB; Eudy, AM; Haroun, T; James, AH; Jayasundara, M; Neil, L, 2018) |
| "Twenty-six out of 93 pregnancies with systemic lupus erythematosus (SLE) experienced flares during pregnancy." | 1.42 | Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study. ( Fei, Y; Hao, D; Li, Y; Liu, Y; Luo, Y; Zhang, L; Zhao, Y, 2015) |
| " And it is safe for pregnant women and fetuses." | 1.40 | [Prospective study of efficacy and safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus]. ( Gao, Z; Hao, D; Jin, D; Liu, J; Xu, D; Zhao, Y, 2014) |
| "Systemic lupus erythematosus was diagnosed in a 34-year-old pregnant woman because of leukopenia, typical skin rash, clinical and biochemical signs of muscle involvement, and positive serology (antinuclear antibodies and anti-double-stranded DNA)." | 1.39 | Myopathy complicating lupus pregnancy. ( d'Amati, G; Framarino-dei-Malatesta, M; Gattamelata, A; Giordano, C; Piccioni, MG; Priori, R; Valesini, G, 2013) |
| "Hydroxychloroquine (HCQ) is a valuable and possibly underused agent in treating mild lupus." | 1.29 | The use of hydroxychloroquine in lupus pregnancy: the British experience. ( Buchanan, NM; Hughes, GR; Khamashta, MA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.70) | 18.7374 |
| 1990's | 9 (8.11) | 18.2507 |
| 2000's | 15 (13.51) | 29.6817 |
| 2010's | 51 (45.95) | 24.3611 |
| 2020's | 33 (29.73) | 2.80 |
| Authors | Studies |
|---|---|
| Haase, I | 2 |
| Fischer-Betz, R | 4 |
| Braga, A | 1 |
| Barros, T | 1 |
| Faria, R | 1 |
| Marinho, A | 1 |
| Carvalheira, G | 1 |
| Rocha, G | 1 |
| Farinha, F | 1 |
| Neves, E | 1 |
| Vasconcelos, C | 1 |
| Braga, J | 1 |
| Tang, C | 2 |
| Si, FL | 1 |
| Yao, YX | 1 |
| Lv, JC | 1 |
| Shi, SF | 1 |
| Chen, YQ | 1 |
| Liu, LJ | 1 |
| Zhang, H | 1 |
| Gernaat, SAM | 1 |
| Simard, JF | 1 |
| Wikström, AK | 1 |
| Svenungsson, E | 1 |
| Arkema, EV | 1 |
| Ntali, S | 1 |
| Nikolopoulos, D | 1 |
| Pantazi, L | 1 |
| Emmanouilidou, E | 1 |
| Papagoras, C | 1 |
| Fanouriakis, A | 2 |
| Dimopoulou, D | 1 |
| Kallitsakis, I | 1 |
| Boki, K | 1 |
| Dania, V | 1 |
| Sidiropoulos, PI | 1 |
| Boumpas, DT | 2 |
| Bertsias, G | 2 |
| Chang, Y | 1 |
| Di, W | 1 |
| Wu, J | 1 |
| Clowse, MEB | 4 |
| Eudy, AM | 4 |
| Balevic, S | 1 |
| Sanders-Schmidler, G | 1 |
| Kosinski, A | 1 |
| Gladman, DD | 2 |
| Molad, Y | 1 |
| Nalli, C | 1 |
| Mokbel, A | 1 |
| Tincani, A | 7 |
| Urowitz, M | 1 |
| Bay, C | 1 |
| van Noord, M | 1 |
| Petri, M | 7 |
| Reynolds, JA | 1 |
| Gayed, M | 1 |
| Khamashta, MA | 7 |
| Leone, F | 1 |
| Toescu, V | 1 |
| Bruce, IN | 1 |
| Giles, I | 1 |
| Teh, LS | 1 |
| McHugh, N | 1 |
| Akil, M | 1 |
| Edwards, CJ | 1 |
| Gordon, C | 1 |
| Tan, Y | 1 |
| Yang, S | 1 |
| Liu, Q | 1 |
| Li, Z | 1 |
| Mu, R | 1 |
| Qiao, J | 1 |
| Cui, L | 1 |
| Silver, R | 1 |
| Craigo, S | 1 |
| Porter, F | 1 |
| Osmundson, SS | 1 |
| Kuller, JA | 1 |
| Norton, ME | 1 |
| Phillips, J | 3 |
| Nathan, E | 3 |
| Graham, D | 3 |
| Marder, W | 1 |
| Rebić, N | 1 |
| Sayre, EC | 1 |
| Zusman, EZ | 1 |
| Amiri, N | 1 |
| Baldwin, C | 1 |
| De Vera, MA | 1 |
| Parikh, SV | 1 |
| Almaani, S | 1 |
| Brodsky, S | 1 |
| Rovin, BH | 1 |
| Saito, K | 1 |
| Mano, C | 1 |
| Tatsumi, T | 1 |
| Ishikawa, T | 1 |
| Sekiguchi, M | 1 |
| Iwahara, Y | 1 |
| Hiramitsu, S | 1 |
| Miyasaka, N | 1 |
| Doms, J | 1 |
| Horisberger, A | 1 |
| Ribi, C | 1 |
| Pregnolato, F | 1 |
| Gerosa, M | 3 |
| Raimondo, MG | 1 |
| Comerio, C | 1 |
| Bartoli, F | 1 |
| Lonati, PA | 1 |
| Borghi, MO | 1 |
| Acaia, B | 1 |
| Ossola, MW | 1 |
| Ferrazzi, E | 1 |
| Trespidi, L | 1 |
| Meroni, PL | 4 |
| Chighizola, CB | 1 |
| Shaharir, SS | 1 |
| Maulana, SA | 1 |
| Shahril, NS | 1 |
| Mohd, R | 1 |
| Mustafar, R | 2 |
| Said, MSM | 1 |
| Rahman, RA | 1 |
| Frishman, M | 1 |
| Radin, M | 2 |
| Schreiber, K | 2 |
| Janardana, R | 1 |
| Haridas, V | 1 |
| Priya, V | 1 |
| Bhat, V | 1 |
| Singh, Y | 1 |
| Rao, VK | 1 |
| Jois, R | 1 |
| Srikantiah, C | 1 |
| Pinto, B | 1 |
| Shobha, V | 1 |
| Latino, JO | 2 |
| Udry, S | 2 |
| Aranda, F | 1 |
| Wingeyer, SP | 1 |
| Romero, DSF | 1 |
| Belizna, C | 1 |
| Larrañaga, G | 1 |
| Liu, Y | 2 |
| Zhang, Y | 1 |
| Wei, Y | 1 |
| Yang, H | 1 |
| Huybrechts, KF | 3 |
| Bateman, BT | 3 |
| Zhu, Y | 1 |
| Straub, L | 1 |
| Mogun, H | 2 |
| Kim, SC | 2 |
| Desai, RJ | 2 |
| Hernandez-Diaz, S | 3 |
| Tziolos, N | 1 |
| Hammad, I | 1 |
| Porter, TF | 1 |
| Abd Rahman, R | 1 |
| Min Tun, K | 1 |
| Kamisan Atan, I | 1 |
| Mohamed Said, MS | 1 |
| Zainuddin, AA | 1 |
| Orefice, V | 1 |
| Ceccarelli, F | 1 |
| Pirone, C | 1 |
| Galoppi, P | 1 |
| Spinelli, FR | 1 |
| Alessandri, C | 1 |
| Brunelli, R | 1 |
| Perrone, G | 1 |
| Conti, F | 1 |
| Tian, Y | 1 |
| Xu, J | 1 |
| Chen, D | 1 |
| Yang, C | 1 |
| Peng, B | 1 |
| Duan, J | 1 |
| Ma, D | 1 |
| Wen, X | 1 |
| Guo, Q | 1 |
| Gao, J | 1 |
| Zhang, G | 1 |
| Xu, K | 1 |
| Zhang, L | 3 |
| Khizroeva, J | 1 |
| Bitsadze, V | 1 |
| Makatsariya, A | 1 |
| Arslanbekova, M | 1 |
| Babaeva, N | 1 |
| Tsibizova, V | 1 |
| Shkoda, A | 1 |
| Makatsariya, N | 1 |
| Tretyakova, M | 1 |
| Solopova, A | 1 |
| Gadaeva, Z | 1 |
| Vorobev, A | 1 |
| Khamani, I | 1 |
| Aslanova, Z | 1 |
| Nakaidze, I | 1 |
| Mischenko, A | 1 |
| Grigoreva, K | 1 |
| Kunesko, N | 1 |
| Egorova, E | 1 |
| Mashkova, T | 1 |
| Gerde, M | 1 |
| Ibarra, E | 1 |
| Mac Kenzie, R | 1 |
| Fernandez Suarez, C | 1 |
| Heer, C | 1 |
| Alvarez, R | 1 |
| Iglesias, M | 1 |
| Balparda, J | 1 |
| Beruti, E | 1 |
| Rubinstein, F | 1 |
| Arachchillage, DRJ | 1 |
| Laffan, M | 1 |
| Lateef, A | 1 |
| Gan, SP | 1 |
| Ong, SG | 1 |
| Lisney, AR | 1 |
| Szelinski, F | 1 |
| Reiter, K | 1 |
| Burmester, GR | 1 |
| Rose, T | 1 |
| Dörner, T | 1 |
| Jayasundara, M | 1 |
| Haroun, T | 1 |
| Neil, L | 1 |
| James, AH | 1 |
| Soh, MC | 1 |
| Nelson-Piercy, C | 1 |
| Westgren, M | 1 |
| McCowan, L | 1 |
| Pasupathy, D | 1 |
| Chaturvedi, S | 1 |
| McCrae, KR | 1 |
| Siega-Riz, AM | 1 |
| Engel, SM | 1 |
| Franceschini, N | 1 |
| Howard, AG | 1 |
| Colla, L | 1 |
| Diena, D | 1 |
| Rossetti, M | 1 |
| Manzione, AM | 1 |
| Marozio, L | 2 |
| Benedetto, C | 1 |
| Biancone, L | 1 |
| Ruffatti, A | 2 |
| Tonello, M | 1 |
| Hoxha, A | 1 |
| Sciascia, S | 4 |
| Cuadrado, MJ | 2 |
| Reshetnyak, T | 1 |
| Costedoat-Chalumeau, N | 6 |
| Morel, N | 2 |
| Andreoli, L | 1 |
| Haladyj, E | 1 |
| Alijotas-Reig, J | 2 |
| Tenti, S | 1 |
| Mayer-Pickel, K | 1 |
| Simchen, MJ | 1 |
| Bertero, MT | 1 |
| De Carolis, S | 2 |
| Ramoni, V | 1 |
| Mekinian, A | 3 |
| Grandone, E | 1 |
| Maina, A | 1 |
| Serrano, F | 1 |
| Pengo, V | 1 |
| Guillotin, V | 1 |
| Bouhet, A | 1 |
| Barnetche, T | 1 |
| Richez, C | 1 |
| Truchetet, ME | 1 |
| Seneschal, J | 1 |
| Duffau, P | 1 |
| Lazaro, E | 2 |
| Balevic, SJ | 1 |
| Cohen-Wolkowiez, M | 1 |
| Green, TP | 1 |
| Schanberg, LE | 1 |
| Barsalou, J | 1 |
| Berhanu, A | 1 |
| Fors-Nieves, C | 1 |
| Shah, U | 1 |
| Brown, P | 1 |
| Laskin, CA | 1 |
| Levesque, K | 1 |
| Buyon, JP | 2 |
| Silverman, ED | 1 |
| Izmirly, PM | 2 |
| Kemp, M | 1 |
| Thomas, W | 1 |
| Placais, L | 1 |
| Carrat, F | 1 |
| Carbillon, L | 2 |
| Nicaise Roland, P | 1 |
| Benbara, A | 1 |
| Cacciatore, C | 1 |
| Fain, O | 2 |
| Li, XY | 1 |
| Zhao, JX | 1 |
| Liu, XY | 1 |
| Bermas, BL | 2 |
| Do, SC | 1 |
| Druzin, ML | 2 |
| Mollerach, FB | 1 |
| Scolnik, M | 1 |
| Catoggio, LJ | 1 |
| Rosa, J | 1 |
| Soriano, ER | 1 |
| Priori, R | 1 |
| Gattamelata, A | 1 |
| d'Amati, G | 1 |
| Giordano, C | 1 |
| Piccioni, MG | 1 |
| Valesini, G | 1 |
| Framarino-dei-Malatesta, M | 1 |
| de Jesús, GR | 1 |
| Rodrigues, G | 1 |
| de Jesús, NR | 1 |
| Levy, RA | 3 |
| Peart, E | 1 |
| Clowse, ME | 2 |
| Cooper, WO | 1 |
| Cheetham, TC | 1 |
| Li, DK | 1 |
| Stein, CM | 1 |
| Callahan, ST | 1 |
| Morgan, TM | 1 |
| Shintani, AK | 1 |
| Chen, N | 1 |
| Griffin, MR | 1 |
| Ray, WA | 1 |
| Hao, D | 2 |
| Xu, D | 1 |
| Liu, J | 1 |
| Jin, D | 1 |
| Zhao, Y | 2 |
| Gao, Z | 1 |
| Masseau, A | 1 |
| De Caroli, S | 1 |
| Ambrozic, A | 1 |
| Botta, A | 2 |
| Le Guern, V | 1 |
| Fritsch-Stork, R | 1 |
| Nicaise-Roland, P | 1 |
| Carbonne, B | 1 |
| Koh, JH | 1 |
| Ko, HS | 1 |
| Kwok, SK | 1 |
| Ju, JH | 1 |
| Park, SH | 1 |
| Salvi, S | 1 |
| di Pasquo, E | 1 |
| Del Sordo, G | 1 |
| Garufi, C | 1 |
| Lanzone, A | 1 |
| De Carolis, MP | 1 |
| Tedeschi, SK | 2 |
| Massarotti, E | 1 |
| Guan, H | 2 |
| Fine, A | 2 |
| Costenbader, KH | 2 |
| Leroux, M | 1 |
| Desveaux, C | 1 |
| Parcevaux, M | 1 |
| Julliac, B | 1 |
| Gouyon, JB | 1 |
| Dallay, D | 1 |
| Pellegrin, JL | 1 |
| Boukerrou, M | 1 |
| Blanco, P | 1 |
| Luo, Y | 1 |
| Fei, Y | 1 |
| Li, Y | 1 |
| Branch, DW | 1 |
| Middeldorp, S | 1 |
| Pavord, S | 1 |
| Roccatello, D | 2 |
| Ruiz-Irastorza, G | 3 |
| Khamashta, M | 2 |
| Hunt, BJ | 2 |
| Talavera-Garcia, E | 1 |
| Lliso, G | 1 |
| Gopalakrishnan, C | 1 |
| Patorno, E | 1 |
| Kaplan, YC | 1 |
| Ozsarfati, J | 1 |
| Nickel, C | 1 |
| Koren, G | 3 |
| Al Marzooqi, A | 1 |
| Leone, A | 1 |
| Al Saleh, J | 1 |
| Bertolaccini, ML | 1 |
| Contento, G | 1 |
| Lennen, R | 1 |
| Sanna, G | 1 |
| Blower, PJ | 1 |
| Ma, MT | 1 |
| Sunassee, K | 1 |
| Girardi, G | 1 |
| Bermas, B | 1 |
| Schioppo, T | 1 |
| Merino Argumánez, C | 1 |
| Sáez de La Fuente, I | 1 |
| Molina Collado, Z | 1 |
| Suárez Pita, D | 1 |
| Mestre Gómez, B | 1 |
| Sanchez Izquierdo, JA | 1 |
| Bazzan, M | 1 |
| Fleury, O | 1 |
| Droitcourt, C | 1 |
| Polard, E | 1 |
| Chevrant-Breton, J | 1 |
| Bérezné, A | 1 |
| Mouthon, L | 1 |
| Currie, C | 1 |
| Wax, JR | 1 |
| Pinette, MG | 1 |
| Blackstone, J | 1 |
| Cartin, A | 1 |
| Iba-Ba, J | 1 |
| Mayi-Tsonga, S | 1 |
| Ibouili Bignoumba, R | 1 |
| Diallo, T | 1 |
| Moussavou Kombila, JB | 1 |
| Coniquet, S | 1 |
| Mihindou Boussougou, C | 1 |
| Boguikouma, JB | 1 |
| Teh, CL | 1 |
| Wong, JS | 1 |
| Ngeh, NK | 1 |
| Loh, WL | 1 |
| Kim, MY | 1 |
| Llanos, C | 1 |
| Le, PU | 1 |
| Guerra, MM | 1 |
| Askanase, AD | 1 |
| Salmon, JE | 1 |
| Partlett, R | 1 |
| Roussou, E | 1 |
| Abarientos, C | 1 |
| Sperber, K | 1 |
| Shapiro, DL | 1 |
| Aronow, WS | 1 |
| Chao, CP | 1 |
| Ash, JY | 1 |
| Ma, L | 1 |
| Lin, B | 1 |
| Wu, DH | 1 |
| Wang, GC | 1 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Nikpour, M | 1 |
| Langen, ES | 1 |
| Chakravarty, EF | 1 |
| Liaquat, M | 1 |
| El-Sayed, YY | 1 |
| Nasonov, EL | 1 |
| Amoura, Z | 2 |
| Duhaut, P | 1 |
| Huong, DL | 1 |
| Sebbough, D | 1 |
| Wechsler, B | 2 |
| Vauthier, D | 1 |
| Denjoy, I | 1 |
| Lupoglazoff, JM | 1 |
| Piette, JC | 2 |
| Cimaz, R | 1 |
| Brucato, A | 1 |
| Meregalli, E | 1 |
| Muscará, M | 1 |
| Sergi, P | 1 |
| Motta, M | 2 |
| Faden, D | 1 |
| Zinzini, E | 1 |
| Lojacono, A | 2 |
| Marchesi, A | 1 |
| Frassi, M | 1 |
| Biasini, C | 1 |
| Zatti, S | 1 |
| Chirico, G | 2 |
| Le Thi Huong, D | 1 |
| Renaud, C | 1 |
| de Montgolfier, I | 1 |
| Vautier-Brouzes, D | 1 |
| Lapillonne, A | 1 |
| Gold, F | 1 |
| Magder, L | 1 |
| Witter, F | 1 |
| Golding, A | 1 |
| Haque, UJ | 1 |
| Giles, JT | 1 |
| Ciardelli, L | 1 |
| Marconi, M | 1 |
| Gasparoni, A | 1 |
| Lima, F | 2 |
| Alves, J | 1 |
| Simpson, J | 1 |
| Hughes, GR | 3 |
| Buchanan, NM | 3 |
| Toubi, E | 1 |
| Kerslake, S | 1 |
| Parke, AL | 2 |
| Rothfield, NF | 1 |
| Parke, A | 1 |
| West, B | 1 |
| Rynes, RI | 1 |
| Vilela, VS | 1 |
| Cataldo, MJ | 1 |
| Ramos, RC | 1 |
| Duarte, JL | 1 |
| Tura, BR | 1 |
| Albuquerque, EM | 1 |
| Jesús, NR | 1 |
| Milazzo, S | 1 |
| Howard, D | 1 |
| Repke, J | 1 |
| Levy, M | 1 |
| Buskila, D | 1 |
| Urowitz, MB | 1 |
| Ross, JB | 1 |
| Garatsos, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis During the Induction of Remission Period-EUROLUPUS vs. RITUXILUP Regimen: A Randomized Study[NCT05207358] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | ||
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome[NCT04624269] | Phase 4 | 384 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441] | Phase 2 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Not started) | ||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
44 reviews available for hydroxychloroquine and Complications, Pregnancy
| Article | Year |
|---|---|
[State of the art: fertility and pregnancy in rheumatic diseases].
Topics: Female; Fertility; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy C | 2021 |
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
Pregnancy-related complications in systemic lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Systemic; Pregnancy; Pregn | 2022 |
Update on pregnancy complications in systemic lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Complication | 2019 |
Pregnancy and Systemic Lupus Erythematosus.
Topics: Adult; Antimalarials; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newborn | 2020 |
Update on Lupus Nephritis: Core Curriculum 2020.
Topics: Adaptive Immunity; Adrenal Cortex Hormones; Age Distribution; Autoantibodies; Autoimmunity; Biopsy; | 2020 |
[Pregnancy with lupus erythematosus-an update].
Topics: Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregna | 2020 |
[Management of the antiphospholipid syndrome in adults].
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Hydr | 2020 |
Hydroxychloroquine and antiphospholipid antibody-related pregnancy morbidity: a systematic review and meta-analysis.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Case-Control Studies; Female; Humans; Hydro | 2020 |
Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
An Update on Biologic Agents During Pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humani | 2020 |
The additional use of hydroxychloroquine can improve the live birth rate in pregnant women with persistent positive antiphospholipid antibodies: A systematic review and meta-analysis.
Topics: Adult; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy Complicat | 2021 |
Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Case-Control Studies; Diabetes, Gestational; Female; HE | 2021 |
Pathogenesis and management of antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; beta 2-Glycoprotein I; Complement Inactiv | 2017 |
Systemic Lupus Erythematosus and Pregnancy.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychlo | 2017 |
Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?
Topics: Adult; Antiphospholipid Syndrome; Cardiovascular Diseases; Female; Humans; Hydroxychloroquine; Lupus | 2017 |
Diagnosis and management of the antiphospholipid syndrome.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; Disease Management; En | 2017 |
Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era.
Topics: Azathioprine; Biological Products; Calcineurin Inhibitors; Cyclophosphamide; Directive Counseling; F | 2018 |
Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis.
Topics: Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Infant, Newborn; | 2018 |
Antiphospholipid syndrome in obstetrics.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; | 2018 |
Systemic lupus erythematosus in pregnancy: high risk, high reward.
Topics: Adult; Counseling; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Lupus Erythematosus | 2019 |
[Rheumatic diseases in pregnancy].
Topics: Europe; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Practice Guidelines as Topic; | 2013 |
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retarda | 2014 |
Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Azathioprine; Cohort Studies; Female; Heart Block; Humans; Hydrox | 2014 |
Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?
Topics: Anti-Inflammatory Agents; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnancy; | 2015 |
Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; | 2015 |
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Cohort Studies; Female; Heparin; H | 2016 |
Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Autoimmune Diseases; Female; Humans; Hydroxychloroquine | 2016 |
Current status and future prospects for the treatment of antiphospholipid syndrome.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; Female; Humans; Hydroxychloroqui | 2016 |
Challenges and treatment options for rheumatoid arthritis during pregnancy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Hydroxychloroquine | 2016 |
Hydroxychloroquine, a potentially lethal drug.
Topics: Adult; Anisocoria; Coma; Connective Tissue Diseases; Emergencies; Female; Heart Arrest; Humans; Hydr | 2017 |
Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnan | 2016 |
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antic | 2017 |
[Pregnancy in systemic sclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Female; Fetal Diseases; Humans; Hydr | 2008 |
The treatment of rheumatoid arthritis during pregnancy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; | 2011 |
Lupus and pregnancy: integrating clues from the bench and bedside.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Azathioprine; Counseli | 2011 |
Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Hydr | 2011 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
Immunosuppressive drug use in pregnancy.
Topics: Adrenal Cortex Hormones; Azathioprine; Breast Feeding; Cyclophosphamide; Cyclosporine; Female; Fetal | 2003 |
[Pleading to maintain hydroxychloroquine throughout Lupus pregnancies].
Topics: Antirheumatic Agents; Disease Progression; Female; Humans; Hydroxychloroquine; Lactation; Lupus Eryt | 2005 |
Rheumatoid arthritis and reproduction.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Immunosuppre | 2007 |
Antimalarial drugs in pregnancy--the North American experience.
Topics: Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus | 1996 |
Antimalarial drugs in the treatment of rheumatological diseases.
Topics: Antimalarials; Chloroquine; Contraindications; Female; Humans; Hydroxychloroquine; Male; Pregnancy; | 1997 |
4 trials available for hydroxychloroquine and Complications, Pregnancy
| Article | Year |
|---|---|
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group.
Topics: Antirheumatic Agents; Birth Weight; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hydr | 2003 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Topics: Antimalarials; Child, Preschool; Contraindications; Female; Fetus; Follow-Up Studies; Hearing Disord | 1996 |
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.
Topics: Adult; Antimalarials; Double-Blind Method; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2001 |
63 other studies available for hydroxychloroquine and Complications, Pregnancy
| Article | Year |
|---|---|
Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal.
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newbor | 2021 |
The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study.
Topics: Adult; Cohort Studies; Female; Glomerulonephritis, IGA; Humans; Hydroxychloroquine; Kidney Function | 2022 |
Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus.
Topics: Diabetes, Gestational; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2022 |
Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study.
Topics: Antibodies, Antiphospholipid; Azathioprine; Female; Glucocorticoids; Humans; Hydroxychloroquine; Inf | 2022 |
Systemic Lupus Erythematosus Increases the Risk of Gestational Diabetes: Truth or Illusion?
Topics: Antirheumatic Agents; Diabetes, Gestational; Female; Humans; Hydroxychloroquine; Illusions; Lupus Er | 2022 |
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine.
Topics: Adolescent; Antirheumatic Agents; Azathioprine; Child; Female; Humans; Hydroxychloroquine; Lupus Ery | 2023 |
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Wei | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
Topics: Abatacept; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirh | 2020 |
Placenta accrete after a frozen-thawed embryo transfer in a systemic lupus erythematosus patient treated with hydroxychloroquine.
Topics: Adult; Blastocyst; Cesarean Section; Cryopreservation; Embryo Transfer; Female; Freezing; Humans; Hy | 2020 |
EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies.
Topics: Adult; Algorithms; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Aspirin; beta 2-Glycop | 2021 |
Adverse pregnancy outcomes among multi-ethnic systemic lupus erythematosus patients in Malaysia.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Mala | 2020 |
Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hydroxychloroquine; India; Infant, Newborn; Lupus Eryt | 2020 |
Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Hy | 2020 |
Hydroxychloroquine early in pregnancy and risk of birth defects.
Topics: Abnormalities, Drug-Induced; Adult; COVID-19; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnan | 2021 |
New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre.
Topics: Adult; Cohort Studies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Malaysia; | 2020 |
Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy Complications | 2021 |
Breastfeeding in women affected by systemic lupus erythematosus: Rate, duration and associated factors.
Topics: Adult; Breast Feeding; Cesarean Section; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2021 |
Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Endothelial Cells; | 2022 |
The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Cohort Studies; Female; Humans; Hydroxychloroquine; Placenta; Pregnancy; | 2021 |
Antithrombotic effects of hydroxychloroquine in a pregnant patient with Antiphospholipid syndrome and recurrent venous thromboembolism.
Topics: Antiphospholipid Syndrome; Antithrombins; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy C | 2017 |
High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Che | 2017 |
Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cesarean Section; Female; Ges | 2018 |
Effect of pregnancy on disease flares in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Antirheumatic Agents; Cohort Studies; Female; Humans; Hydroxychloroquine; Lupus E | 2018 |
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study.
Topics: Administration, Oral; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antiphosphol | 2018 |
Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosu | 2019 |
Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.
Topics: Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; | 2018 |
Obstetrical morbidity related to anti-SSA antibodies: Data from a French monocentric retrospective study.
Topics: Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Aspirin; Databases, Factual; Female; Fran | 2019 |
[Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome].
Topics: Abortion, Habitual; Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2018 |
Too Little of a Good Thing: Hydroxychloroquine in Pregnancy.
Topics: Female; Humans; Hydroxychloroquine; Infant, Newborn; Pregnancy; Pregnancy Complications; Rheumatic D | 2019 |
Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies.
Topics: Adult; Antibodies, Antinuclear; Argentina; Atrioventricular Block; Autoimmune Diseases; Autoimmunity | 2019 |
Myopathy complicating lupus pregnancy.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Biopsy; Drug Therapy, Combination; Female; Hum | 2013 |
Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy.
Topics: Adult; Arthritis; Cohort Studies; Congenital Abnormalities; Female; Fetal Death; Follow-Up Studies; | 2014 |
[Prospective study of efficacy and safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus].
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Compl | 2014 |
Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Apgar Score; Female; Fetal Growth Retardation; Follow-Up Studies; Human | 2015 |
Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy.
Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Humans; Hydroxychloroquine; Logistic Models; Lupu | 2015 |
Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Gluc | 2015 |
Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Connective Tissue | 2015 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; B | 2016 |
Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.
Topics: Adult; Animals; Antimalarials; Antiphospholipid Syndrome; Brain; Complement Activation; Complement C | 2016 |
Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes.
Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Female; Humans; Hydroxy | 2016 |
Reversible ageusia as an adverse effect of hydroxychloroquine treatment.
Topics: Adult; Ageusia; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregna | 2009 |
Cogan's syndrome complicating pregnancy.
Topics: Adult; Anti-Inflammatory Agents; Cogan Syndrome; Female; Humans; Hydroxychloroquine; Pregnancy; Preg | 2009 |
[Dermatomyositis and pregnancy: a case in Gabon].
Topics: Adult; Antirheumatic Agents; Cesarean Section; Dermatomyositis; Female; Gabon; Glucocorticoids; Huma | 2009 |
Systemic lupus erythematosus pregnancies: the Sarawak experience and review of lupus pregnancies in Asia.
Topics: Adult; Antirheumatic Agents; Asia; Cesarean Section; Cross-Sectional Studies; Disease Progression; F | 2011 |
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.
Topics: Antirheumatic Agents; Autoantibodies; Autoantigens; Case-Control Studies; Female; Heart Diseases; Hu | 2010 |
[The safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus].
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Compl | 2011 |
High rate of preterm birth in pregnancies complicated by rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Congenital Abnormalities; Female; Fetal Distress | 2014 |
[Current approaches to prevention and treatment of antiphospholipid syndrome].
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Contraceptives, Oral; Enzyme Inhibitors; | 2003 |
Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al.
Topics: Autoimmune Diseases; Breast Feeding; Child, Preschool; Electroretinography; Female; Humans; Hydroxyc | 2004 |
Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation.
Topics: Antirheumatic Agents; Breast Feeding; Child Development; Female; Follow-Up Studies; Humans; Hydroxyc | 2005 |
[Perinatal consequences of maternal connective tissue diseases: a prospective study of 73 cases].
Topics: Adult; Connective Tissue Diseases; Female; Glucocorticoids; Humans; Hydroxychloroquine; Infant, Newb | 2006 |
Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents.
Topics: Autoimmune Diseases; Azathioprine; Cyclosporine; Female; Humans; Hydroxychloroquine; Immune System; | 2007 |
Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Female; Follo | 1996 |
Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.
Topics: Adult; Antirheumatic Agents; Drug Administration Schedule; Female; Humans; Hydroxychloroquine; Lupus | 1996 |
The use of hydroxychloroquine in lupus pregnancy: the British experience.
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Disc | 1996 |
Antimalarial drugs for rheumatoid disease during pregnancy.
Topics: Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fetus; Humans; Hydroxychloroquin | 1999 |
The treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Child; Chloroquine; Female; Gold; Humans; Hydroxychl | 1977 |
Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience.
Topics: Adult; Female; Humans; Hydroxychloroquine; Kidney; Lupus Erythematosus, Systemic; Maryland; Middle A | 1991 |
Pregnancy outcome following first trimester exposure to chloroquine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Arthritis, Rheumatoid; Chloro | 1991 |
Antimalarial drugs, systemic lupus erythematosus and pregnancy.
Topics: Abortion, Spontaneous; Antimalarials; Chloroquine; Female; Fetal Death; Humans; Hydroxychloroquine; | 1988 |
Letter: Absence of chloroquine-induced ototoxicity in a fetus.
Topics: Abnormalities, Drug-Induced; Abortion, Therapeutic; Adult; Ear; Female; Fetus; Humans; Hydroxychloro | 1974 |